This ingredient is classified as unclassified risk (GIRI score: 2.0/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Chondroitin sulphate (UK spelling) is identical in composition and safety profile to chondroitin sulfate. Widely used for osteoarthritis with a strong safety record. Mild GI effects possible. Use with caution with anticoagulant medications.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Joint Support
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Chondroitin Sulphate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 13:57
Evidence Distribution
-
Observational / other LOW evidence YELLOWAn injectable hyaluronic acid/chondroitin sulfate hydrogel capturing stem cell factors attenuates periodontitis. ↗Liu T et al.. An injectable hyaluronic acid/chondroitin sulfate hydrogel capturing stem cell factors attenuates periodontitis.. Colloids Surf B Biointerfaces. 2026. PMID:41875682.PMID 41875682 ↗Journal Colloids Surf B BiointerfacesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41875682/
-
Observational / other LOW evidence YELLOWIntravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis. ↗Kwon M et al.. Intravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis.. BJU Int. 2026. PMID:41858162.PMID 41858162 ↗Journal BJU IntYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41858162/
-
Observational / other LOW evidence YELLOWAvenanthramide C and chondroitin sulphate promote chondrogenic differentiation of adipose-derived mesenchymal stem cells. ↗Sun P et al.. Avenanthramide C and chondroitin sulphate promote chondrogenic differentiation of adipose-derived mesenchymal stem cells.. Sci Rep. 2026. PMID:41813772.PMID 41813772 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41813772/
-
Observational / other LOW evidence YELLOWDevelopment and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease. ↗Berti M et al.. Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease.. Dis Model Mech. 2026. PMID:41783940.PMID 41783940 ↗Journal Dis Model MechYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41783940/
-
Observational / other LOW evidence YELLOWSelective binding of sulphated glycosaminoglycans induces self-assembly of naphthalene diimide into fluorescent nanofibers. ↗Sharma P et al.. Selective binding of sulphated glycosaminoglycans induces self-assembly of naphthalene diimide into fluorescent nanofibers.. Nanoscale. 2026. PMID:41725531.PMID 41725531 ↗Journal NanoscaleYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41725531/
-
Observational / other LOW evidence YELLOWExtracellular matrix remodeling therapeutic strategies to tackle central nervous system diseases. ↗Domingo-Lopez DA et al.. Extracellular matrix remodeling therapeutic strategies to tackle central nervous system diseases.. Neural Regen Res. 2026. PMID:41641774.PMID 41641774 ↗Journal Neural Regen ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41641774/
-
Observational / other LOW evidence YELLOWBifidobacterium longum CBi0703 lysate modulates oxidative stress induced apoptosis and cartilage related gene expression in SW1353 chondrocytes: in vitro insights into the… ↗Mas-Capdevila A et al.. Bifidobacterium longum CBi0703 lysate modulates oxidative stress induced apoptosis and cartilage related gene expression in SW1353 chondrocytes: in vitro insights into the gut joint axis in Osteoarthritis.. Sci Rep. 2026. PMID:41611974.PMID 41611974 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41611974/
-
Observational / other LOW evidence YELLOWMolecular Changes in CSPG and Glial Scar Markers in Response to Subpial Chondroitinase ABC Treatment Following Spinal Cord Injury. ↗Kisucku00e1 A et al.. Molecular Changes in CSPG and Glial Scar Markers in Response to Subpial Chondroitinase ABC Treatment Following Spinal Cord Injury.. Eur J Neurosci. 2026. PMID:41518155.PMID 41518155 ↗Journal Eur J NeurosciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41518155/
-
Observational / other LOW evidence YELLOWCurcumin-Based Supplement for Vitreous Floaters Post-Nd:YAG Capsulotomy: A Pilot Study. ↗Malandrini A et al.. Curcumin-Based Supplement for Vitreous Floaters Post-Nd:YAG Capsulotomy: A Pilot Study.. Vision (Basel). 2025. PMID:41441556.PMID 41441556 ↗Journal Vision (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41441556/
-
Observational / other LOW evidence YELLOWHyaluronic acid-chondroitin sulphate in overactive bladder: a bridge between pharmacotherapy and advanced therapies. ↗Pischetola A et al.. Hyaluronic acid-chondroitin sulphate in overactive bladder: a bridge between pharmacotherapy and advanced therapies.. Minerva Urol Nephrol. 2025. PMID:41410668.PMID 41410668 ↗Journal Minerva Urol NephrolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41410668/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Chondroitin Sulphate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Chondroitin Sulphate
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.